Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Active:	Yes
Cancer Type:	Colon/Rectal Cancer Gynecologic Cancers	NCT ID:	NCT02628067
Trial Phases:	Phase II	Protocol IDs:	NCT02628067 (primary) 3475-158 2015-002067-41 163196
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp & Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT02628067

Summary

In this study, participants with multiple types of advanced (unresectable and/or
metastatic) solid tumors who have progressed on standard of care therapy will be treated
with pembrolizumab (MK-3475).

Objectives

Current Primary Outcome Measures ^ICMJE (submitted: April 7, 2016)	Objective Response Rate (ORR) [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE (submitted: December 9, 2015)	Objective Response Rate (ORR) [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
Change History	Complete list of historical versions of study NCT02628067 on ClinicalTrials.gov Archive Site

Treatment Sites in Georgia

Georgia Cancer Center for Excellence at Grady
80 Jesse Hill Jr. Drive, SE
Atlanta, GA 30303
404-489-9000
www.gradyhealth.org

South Atlanta Hematology Oncology - Riverdale
253 Upper Riverdale Rd
Suite C
Riverdale, GA 30274

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.